NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocar
Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide. Atherosclerosis of coronary arteries which takes decades to manifest clinically, is the primary predisposing pathologic factor responsible for the development of coronary heart dise
| Condition(s) | STEMI |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide. Atherosclerosis of coronary arteries which takes decades to manifest clinically, is the primary predisposing pathologic factor responsible for the development of coronary heart disease It has been shown that A complex immune and inflammatory pathophysiological process is thought to be crucial for in the initiation and progression of atherosclerotic plaques. Inflammation is one of the main mechanisms in the pathogenesis of atherosclerosis , Destabilization of chronic artery plaques and development of thrombosis, which are the main mechanisms in the pathophysiology of ST-segment elevation myocardial infarction (STEMI). , and the interest to the evaluation |
| Who can participate | Inclusion Criteria: * Patients with age ≥18 years of either sex, with either increase in serum cardiac biomarkers or ECG are STEMI. Exclusion Criteria: * Patients presenting with NSTEMI and unstable angina * Patients with any of these associated conditions that can affect NLR or CRP including * Inflammatory conditions such as collagen-vascular disorders * Acute or chronic infectious diseases. * Auto-immune and neoplastic diseases. * Chronic hepatic diseases. * Renal failure. * Thyroid disorders. * Previous valvular heart disease. |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Sohag University |
| Locations | Sohag, Egypt |
| Start date | 2024-07-01 |
| NCT ID | NCT06491667 |
| Official listing | https://clinicaltrials.gov/study/NCT06491667 |